A panel of advisors to the Food and Drug Administration (FDA) reviewed a new kind of osteoporosis drug on August 13, 2009. The agency is not bound by the recommendations of its advisory panels, but typically follows them.

The drug, denosumab, which may be brand-named Prolia, is a monoclonal antibody given by injection every six months, and it works by inhibiting a protein necessary to cells called osteoclasts, which break down bone.

In a head-to-head comparison with alendronate (Fosamax) published in the February 23, 2006 issue of The New England Journal of Medicine, denosumab increased bone density at the hip and spine at least as well, and in some cases, better than alendronate.